Tvardi Therapeutics, Inc.
TVRD Healthcare Biotechnology
In the quarter to June 2026, revenue grew 20.3%, EPS fell 235.3% and free cash flow fell 57.3%, each against the same quarter a year earlier.
Follow TVRD
Tvardi Therapeutics, Inc. (TVRD) Altman Z-score
Tvardi Therapeutics, Inc.'s Altman Z-score for fiscal 2024 is −5.15, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2024 | −5.15 | 4.27 |
| FY2023 | −9.42 | (19.41) |
| FY2022 | 9.99 | (5.91) |
| FY2021 | 15.90 | (2.84) |
| FY2020 | 18.74 | 13.10 |
| FY2019 | 5.64 | 3.37 |
| FY2018 | 2.27 | (16.01) |
| FY2017 | 18.28 | 12.32 |
| FY2016 | 5.96 | (35.65) |
| FY2015 | 41.61 | — |
How fiscal 2024’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.61 | — | 0.73 | |
| Retained earnings / total assets | (2.62) | — | −3.67 | |
| EBIT / total assets | (0.80) | — | −2.64 | |
| Market value of equity / total liabilities | 0.37 | — | 0.22 | |
| Sales / total assets | 0.20 | — | 0.20 | |
| Altman Z-score | Distress zone | −5.15 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −10.69 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| KTTA Pasithea Therapeutics Corp. compare | 3.0× |
| TVRD Tvardi Therapeutics, Inc. | −5.1× |
| LPCN Lipocine Inc. compare | −7.7× |
| DARE Dare Bioscience, Inc. compare | −8.9× |
| ADAPY Adaptimmune Therapeutics PLC compare | −23.3× |
| CNSY Cerenome, Inc. compare | −44.9× |
| BCDA BioCardia, Inc. compare | −74.8× |
| RVLP RVL Pharmaceuticals PLC compare | — |
| CLVSQ Clovis Oncology, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets